Facilitated search for specific genomic targets by p53 C-terminal basic DNA binding domain

Cancer Biology and Therapy

Volumn 3, Issue 11, 2004, Pages 1102-1108

  Liu, Yuangang ^a   Lagowski, James P ^a   Vanderbeek, Gretchen E ^a   Kulesz Martin, Molly F ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Genome; Non sequence specific DNA; p53; p53as; Structure specific DNA

Indexed keywords

GENOMIC DNA; PROTEIN P21; PROTEIN P53; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DNA;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CHROMATIN; CONTROLLED STUDY; DNA BINDING MOTIF; EUKARYOTE; GENE TARGETING; GENOME; GENOTOXICITY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VIVO STUDY; PROMOTER REGION; PROTEIN BINDING; PROTEIN DNA BINDING; ADENOCARCINOMA; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; GENETICS; LUNG TUMOR; METABOLISM; PHYSIOLOGY; TRANSACTIVATION;

ADENOCARCINOMA; BINDING SITES; CELL CYCLE PROTEINS; CHROMATIN IMMUNOPRECIPITATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA; HUMANS; LUNG NEOPLASMS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 22144452221     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.11.1189     Document Type: Article

References (57)

1. Vogelstein B, LaneD, LevineAJ. Surfing the p53 network. Nature 2000; 408:307-10.
2. Ahn J, Prives C. The C-terminus of p53: The more you learn the less you know. Nat Struct Biol 2001; 8:730-2.
3. Kim E, Deppert W. The complex interactions of p53 with target DNA: We learn as we go. Biochem Cell Biol 2003; 81:141-50.
4. Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell 1992; 71:875-86.
5. Wu Y, Liu Y, Lee L, Miner Z, Kulesz-Martin M. Wild-type alternatively spliced p53: Binding to DNA and interaction with the major p53 protein in vitro and in cells. EMBO J 1994; 13:4823-30.
6. Takenaka I, Morin F, Seizinger BR, Kley N. Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J Biol Chem 1995; 270:5405-11.
7. Lu H, Fisher RP, Bailey P, Levine AJ. The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro. Mol Cell Biol 1997; 17:5923-34.
8. Gu W, RoederR G. Activation of p53 sequence-specific DNA binding by aceylation of the p53 C-terminal domain. Cell 1997; 90:595-606.
9. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 1998; 12:2831-41.
10. Nie Y, Ii HH, Bula CM, Liu X. Stimulation of p53 DNA binding by c-Abl requires the p53 C terminus and tetramerization. Mol Cell Biol 2000; 20:741-8.
11. Ayed A, Mulder FA, Yi GS, Lu Y, Kay LE, Arrowsmith CH. Latent and active p53 are identical in conformation. Nat Struct Biol 2001; 8:756-60.
12. Bayle JH, Elenbaas B, Levine AJ. The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. Proc Natl Acad Sci USA 1995; 92:5729-33.
13. Anderson ME, Woelker B, Reed M, Wang P, Tegtmeyer P. Reciprocal interference between the sequence-specific core and nonspecific C-terminal DNA binding domains of p53: Implications for regulation. Mol Cell Biol 1997; 17:6255-64.
14. Espinosa JM, Emerson BM. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell 2001; 8:57-69.
15. Gohler T, Reimann M, Cherny D, Walter K, Warnecke G, Kim E, et al. Specific interaction of p53 with target binding sites is determined by DNA conformation and is regulated by the C-terminal domain. J Biol Chem 2002; 277:41192-203.
16. Mc Kinney, Kprives C. Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol Cell Biol 2002; 22:6797-808.
17. Luo J, Li M, Tang Y, Laszkowska M, Roeder RG, Gu W. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci USA 2004; 101:2259-64.
18. Reed M, Woelker B, Wang P, Wang Y, Anderson ME, Tegtmeyer P. The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc Natl Acad Sci USA 1995; 92:9455-9.
19. Lee S, Elenbaas B, Levine AJ, Griffith J. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 1995; 81:1013-20.
20. Lee S, Cavallo L, Griffith J. Human p53 binds junctions strongly and facilitates their cleavage. J Biol Chem 1997; 272:7532-9.
21. Dudenhoffer C, Rohaly G, Will K, Deppert W, Wiesmuller L. Specific mismatch recognition in heteroduplex intermediates by p53 suggests a role in fidelity control of homologous recombination. Mol Cell Biol 1998; 18:5332-42.
22. Zotchev SB, Protopopova M, Selivanova G. p53 C-terminal interaction with DNA ends and gaps has opposing effect on specific DNA binding by the core. Nucleic Acids Res 2000; 28:4005-12.
23. Mazur SJ, Sakaguchi K, Appella E, Wang XW, Harris CC, Bohr VA. Preferential binding of tumor suppressor p53 to positively or negatively supercoiled DNA involves the C-terminal domain. J Mol Biol 1999; 292:241-9.
24. Stansel RM, Subramanian D, Griffith JD. p53 binds telomeric single strand overhangs and t-loop junctions in vitro. J Biol Chem 2002; 277:11625-8.
25. Steinmeyer K, Deppert W. DNA binding properties of murine p53. Oncogene 1988; 3:501-7.
26. Kern SE, Kinzler KW, Baker SJ, Nigro JM, Rotter V, Levine AJ, et al. Mutant p53 proteins bind DNA abnormally in vitro. Oncogene 1991; 6:131-6.
27. von Hippel PH, Berg OG. Facilitated target location in biological systems. J Biol Chem 1989; 264:675-8.
28. Shimamoto N. One-dimensional diffusion of proteins along DNA. Its biological and chemical significance revealed by single-molecule measurements. J Biol Chem 1999; 274:15293-6.
29. Jeltsch A, Wenz C, Stahl F, Pingoud A. Linear diffusion of the restriction endonuclease EcoRV on DNA is essential for the in vivo function of the enzyme. EMBO J 1996; 15:5104-11.
30. Gowers DM, Halford SE. Protein motion from nonspecific to specific DNA by three-dimensional routes aided by supercoiling. EMBO J 2003; 22:1410-8.
31. Hsieh M, Brenowitz M. Comparison of the DNA association kinetics of the Lac repressor tetramer, its dimeric mutant LacIadi, and the native dimeric Gal repressor. J Biol Chem 1997; 272:22092-6.
32. Surby MA, Reich NO. Facilitated diffusion of the EcoRI DNA methyltransferase is described by a novel mechanism. Biochemistry 1996; 35:2209-17.
33. Gruskin EA, Lloyd RS. The DNA scanning mechanism of T4 endonuclease V. Effect of NaCl concentration on processive nicking activity. J Biol Chem 1986; 261:9607-13.
34. Viadiu H, Aggarwal AK. Structure of BamHI bound to nonspecific DNA: A model for DNA sliding. Mol Cell 2000; 5:889-95.
35. Kalodimos CG, Biris N, Bonvin AM, Levandoski MM, Guennuegues M, Boelens R, et al. Structure and flexibility adaptation in nonspecific and specific protein-DNA complexes. Science 2004; 305:386-9.
36. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 249:912-5.
37. Liu Y, Asch H, Kulesz-Martin MF. Functional quantification of DNA-binding proteins p53 and estrogen receptor in cells and tumor tissues by DNA affinity immunoblotting. Cancer Res 2001; 61:5402-6.
38. Knights CD, Liu Y, Appella E, Kulesz-Martin M. Defective p53 post-translational modification required for wild type p53 inactivation in malignant epithelial cells with mdm2 gene amplification. J Biol Chem 2003; 278:2890-900.
39. el Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992; 1:45-9.
40. Szak ST, Mays D, Pietenpol JA. Kinetics of p53 binding to promoter sites in vivo. Mol Cell Biol 2001; 21:3375-86.
41. Hoh J, Jin S, Parrado T, Edington J, Levine AJ, Ott J. The p53MH algorithm and its application in detecting p53-responsive genes. Proc Natl Acad Sci USA 2002; 99:8467-72.
42. Szak ST, Pietenpol JA. High affinity insertion/deletion lesion binding by p53. Evidence for a role of the p53 central domain. J Biol Chem 1999; 274:3904-9.
43. Wolcke J, Reimann M, Klumpp M, Gohler T, Kim E, Deppert W. Analysis of p53 "latency" and "activation" by fluorescence correlation spectroscopy. Evidence for different modes of high affinity DNA binding. J Biol Chem 2003; 278:32587-95.
44. Crook T, Marston NJ, Sara EA, Vousden KH. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 1994; 79:817-27.
45. Marston NJ, Crook T, Vousden KH. Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. Oncogene 1994; 9:2707-16.
46. Pellegata NS, Cajot JF, Stanbridge EJ. The basic carboxy-terminal domain of human p53 is dispensable for both transcriptional regulation and inhibition of tumor cell growth. Oncogene 1995; 11:337-49.
47. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995; 83:237-45.
48. Jayaraman L, Moorthy NC, Murthy KG, Manley JL, Bustin M, Prives C. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev 1998; 12:462-72.
49. Almog N, Li R, Peled A, Schwartz D, Wolkowicz R, Goldfinger N, et al. The murine C'-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells. Mol Cell Biol 1997; 17:713-22.
50. Inga A, Storici F, Darden TA, Resnick MA. Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol Cell Biol 2002; 22:8012-25.
51. Jiao Y, Cherny DI, Heim G, Jovin TM, Schaffer TE. Dynamic interactions of p53 with DNA in solution by time-lapse atomic force microscopy. J Mol Biol 2001; 314:233-43.
52. Cohen PA, Mani JC, Lane DP. Characterization of a new intrabody directed against the N-terminal region of human p53. Oncogene 1998; 17:2445-56.
53. Cawley S, Bekiranov S, Ng HH, Kapranov P, Sekinger EA, Kampa D, et al. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 2004; 116:499-509.
54. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421:499-506.
55. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003; 424:516-23.
56. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358:15-6.
57. Zhou X, Wang XW, Xu L, Hagiwara K, Nagashima M, et al. COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis. Cancer Res 1999; 59:843-8.